Pyxis Oncology, Inc. Earnings Per Share (Basic)
Pyxis Oncology, Inc. (PYXS) reported Earnings Per Share (Basic) of -$0.40 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-13
- Pyxis Oncology, Inc. earnings per share, basic for the quarter ending 2026-06-30 was -$0.40.
- Pyxis Oncology, Inc. earnings per share, basic for the quarter ending 2026-03-31 was -$0.37.
- Pyxis Oncology, Inc. earnings per share, basic for the quarter ending 2025-12-31 was -$0.29.
- Pyxis Oncology, Inc. earnings per share, basic for the quarter ending 2025-09-30 was -$0.35.
- Pyxis Oncology, Inc. earnings per share, basic for fiscal 2025 was -$1.28.
- Pyxis Oncology, Inc. earnings per share, basic for fiscal 2024 was -$1.32.
- Pyxis Oncology, Inc. earnings per share, basic for fiscal 2023 was -$1.85.
- Pyxis Oncology, Inc. earnings per share, basic for fiscal 2022 was -$3.65.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$0.40 10-Q · filed 2026-08-13 | -$0.76 10-Q · filed 2026-08-13 | -$1.05 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$1.40 derived: net income ÷ weighted average shares · filed 2026-08-13 |
| 2026-03-31 | -$0.37 10-Q · filed 2026-05-14 | -$0.65 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$1.01 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$1.30 derived: net income ÷ weighted average shares · filed 2026-08-13 |
| 2025-12-31 | -$0.29 derived: net income ÷ weighted average shares · filed 2026-03-23 | -$0.64 derived: net income ÷ weighted average shares · filed 2026-03-23 | -$0.94 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$1.28 10-K · filed 2026-03-23 |
| 2025-09-30 | -$0.35 10-Q · filed 2025-11-03 | -$0.65 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$0.99 10-Q · filed 2025-11-03 | -$1.57 derived: net income ÷ weighted average shares · filed 2026-08-13 |
| 2025-06-30 | -$0.30 10-Q · filed 2026-08-13 | -$0.64 10-Q · filed 2026-08-13 | -$1.22 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$1.57 derived: net income ÷ weighted average shares · filed 2026-08-13 |
| 2025-03-31 | -$0.35 10-Q · filed 2026-05-14 | -$0.93 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$1.28 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$1.56 derived: net income ÷ weighted average shares · filed 2026-08-13 |
| 2024-12-31 | -$0.58 derived: net income ÷ weighted average shares · filed 2026-03-23 | -$0.93 derived: net income ÷ weighted average shares · filed 2026-03-23 | -$1.22 derived: net income ÷ weighted average shares · filed 2026-03-23 | -$1.32 10-K · filed 2026-03-23 |
| 2024-09-30 | -$0.35 10-Q · filed 2025-11-03 | -$0.64 derived: net income ÷ weighted average shares · filed 2025-11-03 | -$0.73 10-Q · filed 2025-11-03 | -$1.06 derived: net income ÷ weighted average shares · filed 2025-11-03 |
| 2024-06-30 | -$0.29 10-Q · filed 2025-08-14 | -$0.37 10-Q · filed 2025-08-14 | -$0.69 derived: net income ÷ weighted average shares · filed 2025-08-14 | -$1.20 derived: net income ÷ weighted average shares · filed 2025-08-14 |
| 2024-03-31 | -$0.06 10-Q · filed 2025-05-15 | -$0.39 derived: net income ÷ weighted average shares · filed 2025-08-14 | -$0.92 derived: net income ÷ weighted average shares · filed 2025-08-14 | -$1.32 derived: net income ÷ weighted average shares · filed 2025-08-14 |
| 2023-12-31 | -$0.35 derived: net income ÷ weighted average shares · filed 2025-03-18 | -$0.90 derived: net income ÷ weighted average shares · filed 2025-03-18 | -$1.32 derived: net income ÷ weighted average shares · filed 2025-03-18 | -$1.85 10-K · filed 2025-03-18 |
| 2023-09-30 | -$0.56 10-Q · filed 2024-11-12 | -$0.98 derived: net income ÷ weighted average shares · filed 2024-11-12 | -$1.52 10-Q · filed 2024-11-12 | -$2.52 derived: net income ÷ weighted average shares · filed 2024-11-12 |
| 2023-06-30 | -$0.41 10-Q · filed 2024-08-14 | -$0.95 10-Q · filed 2024-08-14 | -$1.97 derived: net income ÷ weighted average shares · filed 2024-08-14 | -$2.80 derived: net income ÷ weighted average shares · filed 2024-08-14 |
| 2023-03-31 | -$0.54 10-Q · filed 2024-05-14 | -$1.58 derived: net income ÷ weighted average shares · filed 2024-08-14 | -$2.42 derived: net income ÷ weighted average shares · filed 2024-08-14 | -$3.21 derived: net income ÷ weighted average shares · filed 2024-08-14 |
| 2022-12-31 | -$1.04 derived: net income ÷ weighted average shares · filed 2024-03-21 | -$1.89 derived: net income ÷ weighted average shares · filed 2024-03-21 | -$2.69 derived: net income ÷ weighted average shares · filed 2024-03-21 | -$3.65 10-K · filed 2024-03-21 |
| 2022-09-30 | -$0.85 10-Q · filed 2023-11-07 | -$1.64 derived: net income ÷ weighted average shares · filed 2023-11-07 | -$2.61 10-Q · filed 2023-11-07 | -$3.20 derived: net income ÷ weighted average shares · filed 2023-11-07 |
| 2022-06-30 | -$0.79 10-Q · filed 2023-08-11 | -$1.76 10-Q · filed 2023-08-11 | -$2.35 derived: net income ÷ weighted average shares · filed 2023-08-11 | -$3.67 derived: net income ÷ weighted average shares · filed 2023-08-11 |
| 2022-03-31 | -$0.97 10-Q · filed 2023-05-11 | -$1.56 derived: net income ÷ weighted average shares · filed 2023-08-11 | -$2.95 derived: net income ÷ weighted average shares · filed 2023-08-11 | -$4.34 derived: net income ÷ weighted average shares · filed 2023-08-11 |
| 2021-12-31 | -$0.57 derived: net income ÷ weighted average shares · filed 2023-03-22 | -$1.99 derived: net income ÷ weighted average shares · filed 2023-03-22 | -$3.60 derived: net income ÷ weighted average shares · filed 2023-03-22 | -$8.95 10-K · filed 2023-03-22 |
| 2021-09-30 | -$8.96 10-Q · filed 2022-11-01 | -$14.62 derived: net income ÷ weighted average shares · filed 2022-11-01 | -$40.27 10-Q · filed 2022-11-01 | |
| 2021-06-30 | -$5.54 10-Q · filed 2022-08-15 | -$31.86 10-Q · filed 2022-08-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |